Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tiffany & Co. (TIF), Merck & Co., Inc. (MRK), Zimmer Holdings, Inc. (ZMH): These Companies Are Achieving Impressive Returns on Equity and Reducing Debt

Page 1 of 2

When it comes to investing, obviously making money is key and the best way to make money is to find the most profitable company set to generate huge amounts of cash in the future. More cash usually leads to a higher stock price and a fatter bank balance means there is potential for dividend checks, windfall payouts, or other shareholder returns.

It is difficult trying to find these elusive companies, but through a combination of historic ratios and analyst predictions, I believe that I may have found several that are set to power forward with plenty of cash for the future.

Tiffany & Co. (NYSE:TIF)

As a starting point, I began searching for companies that had a good profit margin, in particular, an earnings-before-interest-and-tax margin of around 20%, which indicates a good flow of cash in to the company’s coffers. Secondly, using historic figures, I started looking for companies that had achieved a five-year average return-on-shareholder-equity greater than 15%, to highlight the companies that had consistently delivered a good return on shareholder capital.

Lastly, I searched through analyst predictions and reports to whittle down the remaining candidates looking for companies that were predicted to improve their gearing ratio by at least 50% over the next three years. For example, a company’s net debt to shareholder equity ratio should fall by 50% over the next three years, indicating improving free cash flow, fiscal prudence, and balance sheet strength.

Note: for the purpose of this piece, gearing is total debt divided by shareholder equity.

The results

First up is luxury jewelry producer Tiffany & Co. (NYSE:TIF). Tiffany & Co. (NYSE:TIF) has achieved a 15.9% return on shareholder equity on average during the past five years — a consistent, high level of return. In addition, the company’s earnings-before-interest-and-tax margin during 2012 was 18.7%, indicating a strong level of cash generation.

Company EBIT margin, FY 2012 ROE 5-YR average
Tiffany 18.70% 15.90%

From a gearing perspective, Tiffany & Co. (NYSE:TIF)’s wide profit margin and strong return on equity mean that the company’s level of gearing is projected to fall rapidly over the next few years. According to estimates, the company is expected to reduce its gearing by around 30% every year for the next five years, which should lead to a higher share price and more returns over the next few years.

Next up, biotechnology

Next is biotech company Merck & Co., Inc. (NYSE:MRK). Merck & Co., Inc. (NYSE:MRK) has recently fallen out of favor with investors after a poor first quarter but the company is still generating a lot of cash and producing a good return on shareholder equity. Over the past five years, Merck has produced an average return-on-equity of 16.6%, partly down to the company’s wide EBIT margin, which came in at 22.2% of revenue during 2012.

Company EBIT margin, 2012 ROE 5-YR average
Merck 22.20% 16.60%

With such a wide EBIT margin, Merck & Co., Inc. (NYSE:MRK) has a strong cash flow and analysts predict that the company’s gearing level will turn negative (move into a net cash balance) this year. Indeed, the company’s wide profit margin means that even after losing the exclusive manufacturing rights to some of its key drugs, it is still set to churn out cash for the next few years, which will open the door to additional stock repurchase programs like the $5 billion buyback that the company has recently announced.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!